BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

BeyondSpring (NASDAQ: BYSI) will participate at the Immuno-Oncology 360° Conference in Boston, February 10-12, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

BeyondSpring (NASDAQ: BYSI) will participate at the Immuno-Oncology 360° Conference in Boston, February 10-12, 2026. Dr. Lan Huang, Co-Founder, Chairman and CEO, will present on Plinabulin on February 11, 2026, 4:55–5:10 PM ET in the Sheraton Boston Grand Ballroom.

Presentation covers Plinabulin’s mechanism and translational strategy to enhance PD-1/PD-L1 blockade; slides will be posted afterward on the company’s Posters and Presentations webpage.

Argus Feb 9 session

+0.67% close to close Open Argus

Details

News Market Reaction – BYSI

On Feb 9, the day this news came out, BYSI closed 0.67% above the previous close.

Data tracked by StockTitan Argus for the Feb 9 session.

Historical Context

4 past events · Latest: Dec 12

4 events

Dec 12
Clinical trial data

24h Move

-3.2%

ESMO Asia DUBLIN‑3 Asian subset OS and neutropenia results for plinabulin combo.
Dec 11
Clinical trial data

24h Move

+7.9%

Post‑hoc DUBLIN‑3 analyses showing survival benefit after anti‑PD-(L)1 therapy.
Nov 12
Earnings and update

24h Move

-3.6%

Q3 2025 results plus NSCLC cohort and SEED divestiture/milestones update.
Aug 13
Earnings and update

24h Move

-0.5%

Q2 2025 financials and promising post‑PD‑1/L1 NSCLC data for Plinabulin.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immuno-oncology, PD-1/L1, biomarkers

3 terms

immuno-oncology medical

"a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

PD-1/L1 medical

"designed to enhance PD-1/PD-LD blockade and highlight Plinabulin’s unique mechanism"

PD-1/PD-L1 denotes a pair of proteins involved in the immune system’s “brakes” that some cancers use to hide from immune cells; drugs that target PD-1 or PD-L1 release those brakes and allow the immune system to attack tumors. Investors track PD-1/PD-L1 therapies because they represent a proven class of cancer treatments with broad clinical use, regulatory pathways, and significant revenue potential, while trial results and approvals can sharply affect a biotech’s value.

biomarkers medical

"Track Number: 1. Translational Science & Biomarkers – Expanding Therapeutic Horizons"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

02/09/2026 - 07:15 AM EST

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in the Immuno-Oncology 360° (IO360°) Conference 2026, held February 10-12, 2026 in Boston, MA.

Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD blockade and highlight Plinabulin’s unique mechanism of action and clinical development strategy.

Presentation Details:
Title: Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin
Track Number: 1. Translational Science & Biomarkers – Expanding Therapeutic Horizons
Date: Wednesday, February 11, 2026
Time: 4:55PM to 5:10PM ET
Location: Sheraton Boston Hotel, Track 1, Grand Ballroom

Following the presentation, the slides will also be available on the “Posters and Presentations” page of the Company’s website.

About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin’s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. Learn more at https://beyondspringpharma.com.

Investor Contact: IR@beyondspringpharma.com
Media Contact: PR@beyondspringpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will BeyondSpring (BYSI) present Plinabulin at the IO360° Conference in 2026?

BeyondSpring will present on Wednesday, February 11, 2026, from 4:55 PM to 5:10 PM ET. According to the company, Dr. Lan Huang will speak in Track 1 (Translational Science & Biomarkers) at the Sheraton Boston Grand Ballroom about Plinabulin and PD-1/PD-L1 resistance.

What topic will Dr. Lan Huang cover for BeyondSpring (BYSI) at IO360° 2026?

Dr. Lan Huang will discuss overcoming PD-1/PD-L1 resistance with Plinabulin in a translational context. According to the company, the talk will highlight Plinabulin’s unique mechanism of action and clinical development strategy aimed at enhancing PD-1/PD-L1 blockade.

Where can investors find BeyondSpring (BYSI) presentation slides after the IO360° session?

Presentation slides will be posted on the company’s Posters and Presentations page after the session. According to the company, investors can access the slides via BeyondSpring’s website following the February 11, 2026 presentation for review and reference.

How long is BeyondSpring’s (BYSI) IO360° presentation and which conference track is it on?

The presentation runs for 15 minutes, from 4:55 PM to 5:10 PM ET on February 11, 2026. According to the company, the talk is in Track 1: Translational Science & Biomarkers at the Immuno-Oncology 360° conference.

What will the BeyondSpring (BYSI) IO360° presentation imply for Plinabulin’s development timeline?

The presentation communicates translational insights and clinical strategy but does not announce new trial results or dates. According to the company, the session focuses on mechanism of action and development approach rather than specific regulatory or enrollment milestones.

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference